Pieris Achieves Fourth Milestone Payment In Daiichi Sankyo, Inc. (4568.t) Collaboration To Develop Anticalin® Therapeutics
1/13/2014 7:53:14 AM
FREISING, Germany--(BUSINESS WIRE)--Pieris AG has achieved the third milestone for its lead Anticalin® program with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), triggering an undisclosed payment, the company announced today. This milestone marks in total the fourth milestone achieved for the parties’ two R&D collaborative projects. Specifically, the milestone achieved was the progression of an Anticalin drug candidate through a non-GLP toxicity study in non-human primates. In 2013, Pieris transferred the program to Daiichi Sankyo, which successfully carried out this study.
Help employers find you! Check out all the jobs and post your resume.
comments powered by